StocksFundsScreenerSectorsWatchlists
CABA

CABA - Cabaletta Bio Inc Stock Price, Fair Value and News

13.30USD-0.67 (-4.80%)Market Closed

Market Summary

CABA
USD13.30-0.67
Market Closed
-4.80%

CABA Stock Price

View Fullscreen

CABA RSI Chart

CABA Valuation

Market Cap

641.6M

Price/Earnings (Trailing)

-9.48

Price/Free Cashflow

-11.83

CABA Price/Sales (Trailing)

CABA Profitability

Return on Equity

-28.65%

Return on Assets

-26.68%

Free Cashflow Yield

-8.45%

CABA Fundamentals

CABA Earnings

Earnings (TTM)

-67.7M

Earnings Growth (Yr)

-33.1%

Earnings Growth (Qtr)

-26.98%

Breaking Down CABA Revenue

Last 7 days

-21.9%

Last 30 days

-26.6%

Last 90 days

-31.7%

Trailing 12 Months

58.5%

How does CABA drawdown profile look like?

CABA Financial Health

Current Ratio

15.29

CABA Investor Care

Shares Dilution (1Y)

53.92%

Diluted EPS (TTM)

-1.66

Tracking the Latest Insider Buys and Sells of Cabaletta Bio Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 19, 2024
binder gwendolyn
acquired
11,110
1.01
11,000
see remarks
Jan 19, 2024
binder gwendolyn
sold
-215,439
19.5854
-11,000
see remarks
Dec 19, 2023
binder gwendolyn
acquired
11,110
1.01
11,000
see remarks
Dec 19, 2023
binder gwendolyn
sold
-240,789
21.8899
-11,000
see remarks
Nov 20, 2023
binder gwendolyn
acquired
11,110
1.01
11,000
see remarks
Nov 20, 2023
binder gwendolyn
sold
-196,014
17.8194
-11,000
see remarks
Oct 19, 2023
binder gwendolyn
acquired
11,110
1.01
11,000
see remarks
Oct 19, 2023
binder gwendolyn
sold
-146,921
13.3564
-11,000
see remarks
Sep 19, 2023
binder gwendolyn
sold
-193,220
17.5654
-11,000
see remarks
Sep 19, 2023
binder gwendolyn
acquired
11,110
1.01
11,000
see remarks

1–10 of 39

Which funds bought or sold CABA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
Capital Advisors, Ltd. LLC
unchanged
-
-1,000
1,000
-%
Apr 18, 2024
Allspring Global Investments Holdings, LLC
sold off
-100
-26,422
-
-%
Apr 11, 2024
CHURCHILL MANAGEMENT Corp
reduced
-5.57
-325,283
795,098
0.01%
Apr 11, 2024
Fortitude Family Office, LLC
unchanged
-
-1,477
4,470
-%
Apr 05, 2024
CWM, LLC
new
-
-
-
-%
Apr 05, 2024
GAMMA Investing LLC
reduced
-78.57
-236
51.00
-%
Mar 22, 2024
PNC FINANCIAL SERVICES GROUP, INC.
reduced
-12.21
3,700
15,663
-%
Mar 11, 2024
VANGUARD GROUP INC
added
8.32
18,440,200
48,394,800
-%
Mar 01, 2024
GOLDMAN SACHS GROUP INC
added
58.73
6,244,630
10,811,400
-%
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
127,008
388,579
-%

1–10 of 44

Are Funds Buying or Selling CABA?

Are funds buying CABA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CABA
No. of Funds

Unveiling Cabaletta Bio Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
commodore capital lp
4.4%
1,900,000
SC 13G/A
Feb 14, 2024
lynx1 capital management lp
4.99%
2,139,644
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
6.4%
2,563,952
SC 13G/A
Feb 14, 2024
cormorant asset management, lp
0.00%
0
SC 13G/A
Feb 14, 2024
baker bros. advisors lp
3.4%
1,457,626
SC 13G/A
Feb 14, 2024
alger associates inc
7.8%
3,326,401
SC 13G/A
Feb 13, 2024
bain capital life sciences opportunities iii, lp
4.7%
2e+06
SC 13G/A
Feb 13, 2024
nichtberger steven
5.4%
2,668,756
SC 13G/A
Feb 12, 2024
flynn james e
3.60%
1,543,477
SC 13G/A
Feb 07, 2024
adage capital partners gp, l.l.c.
9.47%
3,864,475
SC 13G/A

Recent SEC filings of Cabaletta Bio Inc

View All Filings
Date Filed Form Type Document
Mar 21, 2024
10-K
Annual Report
Mar 21, 2024
8-K
Current Report
Mar 21, 2024
S-3ASR
S-3ASR
Mar 21, 2024
S-8
Employee Benefits Plan
Mar 20, 2024
8-K
Current Report
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading
Mar 04, 2024
4
Insider Trading

Peers (Alternatives to Cabaletta Bio Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
38.7B
6.8B
-1.66% -28.18%
-8.22
5.66
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.2B
1.8B
-2.46% -28.84%
-41.3
9.94
76.23% 61.08%
16.7B
2.4B
4.57% -8.46%
99.75
6.91
15.42% 18.43%
11.8B
3.7B
-10.11% -29.11%
19.67
3.18
8.87% 75.42%
MID-CAP
5.7B
396.6M
-14.37% -42.33%
-10.84
14.45
425.83% 18.94%
4.4B
-
-13.59% 50.21%
-6.66
60.35
54.84% -34.79%
3.2B
270.6M
-13.81% -4.67%
-13.46
11.9
440.80% -27.84%
2.8B
726.4M
-9.91% -15.82%
-45.19
3.81
40.45% 71.62%
2.8B
240.7M
-20.67% -25.33%
-9.33
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-10.64% -8.42%
24.94
4.47
85.90% -14.05%
558.4M
983.7M
-17.39% -51.52%
-1.02
0.57
-50.36% 17.16%
409.4M
881.7K
-0.38% 387.14%
-9.18
466.16
-77.61% -5.33%
226.2M
4.9M
-10.29% -2.81%
-1.67
46.49
-54.97% 51.71%
6.0M
2.1M
59.81% 33.59%
-0.22
2.14
-13.45% 66.37%

Cabaletta Bio Inc News

Latest updates
MarketBeat18 Apr 202406:17 am
CNN26 Mar 202411:16 am
InvestorPlace21 Mar 202407:00 am

Cabaletta Bio Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32018Q4
Assets46.4%25417318510311792.0010211412612310710711512212813514175.0034.00
  Current Assets47.1%24416617896.0010988.0099.0011112512110510611411912313414172.0034.00
    Cash Equivalents67.3%19311612894.0082.0061.0047.0060.0012211899.0097.0010110911213113671.0033.00
  Net PPE27.7%3.002.002.003.003.003.002.001.001.001.002.001.001.001.001.001.001.001.00-
Liabilities41.2%17.0012.0010.0012.0012.00---8.00----------
  Current Liabilities50.7%16.0011.008.009.009.006.006.007.008.006.006.004.005.004.003.003.003.003.001.00
Shareholder's Equity46.8%23616117492.0010586.0096.00107118117101103110118125132138--
  Retained Earnings-9.8%-233-212-195-181-165-149-138-125-112-98.70-87.14-76.00-66.30-56.99-48.60-40.44-32.96-27.56-12.45
  Additional Paid-In Capital25.7%4693733702732702362342322312151881791761741731721711.002.00
Shares Outstanding14.8%48.0042.0040.0031.0029.0029.0029.0029.0029.0028.0025.0024.00-------
Float---494---29.00---205---214144---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-30.5%-16,448-12,604-11,889-12,608-12,131-9,914-11,526-12,809-10,515-8,344-6,580-8,670-9,173-5,024-7,642-4,931-7,883-2,076-3,821-2,265-
  Share Based Compensation1.4%3,0513,0092,8032,4801,5781,7311,7771,8111,6011,5081,3851,3101,3211,1271,067873819569416496-
Cashflow From Investing1847.7%1,136-65.00-48,14224,620-31623,908-898-49,9118491,7701,0272,3531,8911,471-11,117-226-273-40.00-200-180-
Cashflow From Financing94848.0%93,04998.0094,25822632,891-40.0051.0013,62825,3397,7712,16532.00135-147-44.0073,319-2,101-95649,663-

CABA Income Statement

2023-12-31
Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:  
Research and development$ 55,424$ 39,300
General and administrative19,23614,839
Total operating expenses74,66054,139
Loss from operations(74,660)(54,139)
Other income:  
Interest income6,9851,164
Net loss(67,675)(52,975)
Other comprehensive income (loss):  
Net unrealized income (loss) on available-for-sale investments, net of tax86(47)
Net comprehensive loss$ (67,589)$ (53,022)
Net loss per share of voting and non-voting common stock, basic$ (1.65)$ (1.81)
Net loss per share of voting and non-voting common stock, diluted$ (1.65)$ (1.81)

CABA Balance Sheet

2023-12-31
Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 193,238,000$ 81,607,000
Short-term investments48,011,00024,940,000
Prepaid expenses and other current assets3,241,0002,287,000
Total current assets244,490,000108,834,000
Property and equipment, net2,541,0002,578,000
Operating lease right-of-use assets4,910,0004,991,000
Other assets1,709,000565,000
Total Assets253,650,000116,968,000
Current liabilities:  
Accounts payable4,547,0002,463,000
Accrued and other current liabilities7,887,0004,847,000
Operating lease liabilities, current portion3,560,0002,179,000
Total current liabilities15,994,0009,489,000
Operating lease liabilities, net of current portion1,458,0002,959,000
Total Liabilities17,452,00012,448,000
Commitments and contingencies (see Notes 6 and 7)
Stockholders’ equity:  
Preferred stock, $0.00001 par value: 10,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued or outstanding at December 31, 2023 or 202200
Voting and non-voting common stock, $0.00001 par value: 150,000,000 (143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2023 and December 31, 2022; 47,823,232 (46,378,937 voting and 1,444,295 non-voting) shares issued and outstanding as of December 31, 2023 and 29,445,134 (27,584,375 voting and 1,860,759 non-voting) shares issued and outstanding as of December 31, 202200
Additional paid-in capital469,396,000270,129,000
Accumulated other comprehensive income (loss)39,000(47,000)
Accumulated deficit(233,237,000)(165,562,000)
Total stockholders’ equity236,198,000104,520,000
Total liabilities and stockholders’ equity$ 253,650,000$ 116,968,000
CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; CABA-201, a 4-1BB-containing CD19-CAR T investigational therapy, for the treatment of severe autoimmune diseases; PLA2R-CAART, a discovery stage product to treat patients with PLA2R-associated membranous nephropathy; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEcabalettabio.com
 INDUSTRYBiotechnology
 EMPLOYEES77

Cabaletta Bio Inc Frequently Asked Questions


What is the ticker symbol for Cabaletta Bio Inc? What does CABA stand for in stocks?

CABA is the stock ticker symbol of Cabaletta Bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cabaletta Bio Inc (CABA)?

As of Fri Apr 19 2024, market cap of Cabaletta Bio Inc is 641.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CABA stock?

You can check CABA's fair value in chart for subscribers.

What is the fair value of CABA stock?

You can check CABA's fair value in chart for subscribers. The fair value of Cabaletta Bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Cabaletta Bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CABA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Cabaletta Bio Inc a good stock to buy?

The fair value guage provides a quick view whether CABA is over valued or under valued. Whether Cabaletta Bio Inc is cheap or expensive depends on the assumptions which impact Cabaletta Bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CABA.